Henrijette Richter


Joined in 2014


Henrijette Richter is Partner at Sofinnova Partners, Paris. She joined in 2014 from Novo Seeds (part of Novo A/S) where she was involved in the establishment of the group in 2007. While at Novo Seeds Henrijette was instrumental in the creation, financing and building of companies such as Cytoguide, Orphazyme, Avilex Pharma, EpiTherapeutics (sold to Gilead) and Lysogene. Henrijette is a scientist by training and started her career at Novo Nordisk conducting her PhD in the area of obesity and GH signalling. Before joining Sunstone Capital in 2004, Henrijette was a postdoctoral fellow at the MIT Center for Cancer Research (MA). Henrijette invested in and  is a board member of Asceneuron (CH), Delinia and Chairwoman of the board of iOmx.  She is a member of WITH (Women innovating together in Healthcare).